AB 836
Alternative Names: AB-836Latest Information Update: 21 Aug 2023
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine; Enantigen Therapeutics
- Developer Arbutus Biopharma
- Class Antivirals; Small molecules
- Mechanism of Action Capsid protein inhibitors; Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 21 Jun 2023 Pharmacodynamics data from a phase Ia/Ib in Hepatitis B at the European Association for the Study of the Liver Congress 2023 (EASL-2023) .
- 01 Nov 2022 Discontinued - Phase-I for Hepatitis B in New Zealand (PO) (due to safety issue)
- 25 Jun 2022 Updated efficacy and safety data from a phase Ia/Ib trial in Hepatitis B released by Arbutus Biopharma